COMP <GO>
INNV vs ABBV // 10Y YIELD & FRED MACRO BETA
InnovAge Holding Corp. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: INNV 1
— ABBV 10
■ METRIC PARITY
LAST: $9.24 (+1.54%) • MKT CAP: $1.26B
macro-sensitivity
—
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INNV VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INNV | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.00% | 70.20% | -52.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.20% | 29.00% | -39.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.11% | 3.47% | -1.36 | ABBV | /fcf-yield <GO> |
| Operating Margin | -3.50% | 24.60% | -28.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -3.60% | 6.90% | -10.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 11.80% | 8.60% | +3.20 | INNV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.47 | 5.33 | -0.86 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 45.7 | 65.1 | -19.38 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.26B | $513.86B | -$512.60B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INNV REV | ABBV REV | INNV GROSS % | ABBV GROSS % | INNV FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $853.7M | $61.16B | 18.0% | 70.2% | $26.6M | $17.82B |
| FY 2024 | $763.9M | $56.33B | 17.3% | 70.0% | -$44.8M | $17.83B |
| FY 2023 | $688.1M | $54.32B | — | — | $20.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INNV // BETA —
ABBV // BETA 1.15